Salesforce vs Outlook Therapeutics Which Is a Smarter Choice?

Salesforce and Outlook Therapeutics are two companies in the stock market that operate in completely different industries. Salesforce is a well-known customer relationship management software provider, while Outlook Therapeutics focuses on developing and commercializing innovative ophthalmic products. Both companies have seen fluctuations in their stock performance over the years, with Salesforce often being viewed as a more stable investment option due to its strong market presence. However, Outlook Therapeutics has shown potential for growth with its cutting-edge products in the medical field. Investors should carefully consider their investment goals and risk tolerance when choosing between Salesforce and Outlook Therapeutics stocks.

Salesforce or Outlook Therapeutics?

When comparing Salesforce and Outlook Therapeutics, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Salesforce and Outlook Therapeutics.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Salesforce has a dividend yield of 0.47%, while Outlook Therapeutics has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Salesforce reports a 5-year dividend growth of 0.00% year and a payout ratio of 13.71%. On the other hand, Outlook Therapeutics reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Salesforce P/E ratio at 58.49 and Outlook Therapeutics's P/E ratio at -1.60. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Salesforce P/B ratio is 5.72 while Outlook Therapeutics's P/B ratio is -1.80.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Salesforce has seen a 5-year revenue growth of 1.16%, while Outlook Therapeutics's is -1.00%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Salesforce's ROE at 9.58% and Outlook Therapeutics's ROE at 146.56%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $325.25 for Salesforce and $6.21 for Outlook Therapeutics. Over the past year, Salesforce's prices ranged from $211.76 to $344.87, with a yearly change of 62.86%. Outlook Therapeutics's prices fluctuated between $4.61 and $12.85, with a yearly change of 178.74%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.